Your session is about to expire
← Back to Search
Atezolizumab +/- Bevacizumab for Alveolar Soft Part Sarcoma
Study Summary
This trial is studying how well atezolizumab or atezolizumab plus bevacizumab works in treating patients with alveolar soft part sarcoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have issues with wound healing, heart conditions, stomach problems, or allergies to medications.My cancer is a type that can't be removed by surgery and has not responded to a specific treatment.My ASPS is spreading and causing more symptoms like pain.My alveolar soft part sarcoma cannot be cured with surgery.My condition worsened after taking atezolizumab alone.I do not have specific brain or nervous system conditions.I do not have liver disease, autoimmune diseases, or other specified medical conditions.I meet the age, disease progression, and surgery criteria for Bevacizumab treatment.I don't have ongoing issues with protein in my urine, bleeding, or blood clots.I do not have an infection, am not on excluded medications, and haven't had recent surgery.I am at least 2 years old for monotherapy or 18 for combination therapy.I am mostly self-sufficient and can carry out daily activities.My liver is functioning within the required range.It's been over 6 weeks since my last certain chemotherapy treatment.I have been treated with anti-PD-1 or anti-PD-L1 drugs before.I have previously been treated with anti-CTLA-4 therapy.I am currently taking or have taken drugs that affect my immune system.I am not pregnant, do not have HIV, and do not have any uncontrolled illnesses.My condition worsened despite being treated with atezolizumab.I have a specific type of cancer that has spread and cannot be surgically removed.I meet the age requirements for atezolizumab treatment.I can take care of myself and am up and about more than half of my waking hours.My kidneys are functioning well enough to filter waste.I meet the requirements for time since my last cancer treatment.My cancer diagnosis has been confirmed by the pathology department where I am enrolled.I have a tumor that can be measured with imaging or physical exam.I am willing to give samples for research.I may have had a live vaccine recently, but it's up to my doctor if I can join.I am on blood thinners for treatment.You are expected to live for at least 3 more months.
- Group 1: Arm I (atezolizumab)
- Group 2: Arm II (atezolizumab, bevacizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are patients being recruited for this research project at this time?
"The trial, as stated on the website clinicaltrials.gov, is recruiting patients right now. The original posting was on March 3rd 2017 with the latest edit being November 9th 2022."
What are some of the conditions that Atezolizumab has been shown to help?
"Atezolizumab is an immunotherapy drug that can be used to treat non-small cell lung carcinoma, postoperative, and recurrent non-squamous non-small cell lung cancer."
How many different medical clinics are participating in this study?
"37 hospitals and clinics are running this clinical trial, such as Keck Medicine of USC Buena Park in Buena Park, Keck Medicine of USC Koreatown in Phoenix, Mayo Clinic Hospital in Arizona in North Haven."
How many patients are being treated with this new medication?
"In order to conduct this trial, 62 patients who meet the pre-determined inclusion criteria are required. The research can be conducted at multiple sites, such as Keck Medicine of USC Buena Park in Buena Park, Arizona and Keck Medicine of USC Koreatown in Phoenix, Connecticut."
Can you elaborate on how Atezolizumab has been studied in the past?
"Atezolizumab was first studied in 2004 at Memoral Sloan Kettering Basking Ridge. 1116 trials have completed since then, with 645 more currently underway. Buena Park, Arizona is one of the many locations where these active studies are being conducted."
What are the short- and long-term risks of Atezolizumab?
"Atezolizumab's safety is rated a 2. This comes from it being in Phase 2 of testing, where there are preliminary signs of safety but no data supporting efficacy."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger